Akebia Therapeutics AKBA has seen its share price rise after it gained FDA approval for Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in late March ...

Akebia Therapeutics (NASDAQ:AKBA), which received an FDA nod for its kidney disease therapy Vafseo last year, traded sharply lower after the company’s Q4 earnings update disappointed Wall Street.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 13 Stocks Under $5 With High Upside Potential. On May 29, Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Akebia Therapeutics ...

Akebia Therapeutics (AKBA) stock rose after the company regained full rights to kidney disease therapy Vafseo in the U.S. Read more here.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 best healthcare penny stocks to buy according to analysts.On June 2, the company reported that it had granted options to purchase an ...